"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...

BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...

To test the accuracy of the Octet ® assay, Fc-fusion protein was spiked into CCM and HCP matrices at known concentrations in ...

A study looking at the biophysical properties of an abnormal protein driving cancer cells is giving scientists new therapeutic clues for how to treat ependymoma, the third most common childhood brain ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

HCW Biologics presents HCW9206, a novel fusion protein enhancing CAR-T cell therapy's efficacy and cost-effectiveness against diseases. HCW Biologics Inc. has announced promising results from studies ...

CRDMO WuXi Biologics and HanchorBio, a clinical-stage biotech company focusing on immunotherapies for oncology and autoimmune diseases, signed a collaboration agreement to support the development and ...

This highlights an important preclinical model that could be successful in humans. The notoriously persistent, difficult-to-treat, lifelong and contagious virus—which insidiously attacks the ...